Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ATX2417 in Healthy Volunteers
NCT02316912Phase 1Completed
- Sponsor
- Atopix Therapeutics
- Start
- Feb 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ATX2417 in asthma and atopic dermatitis (AD) (4 arms), sponsored by Atopix Therapeutics. Primary endpoint: Number of subjects with adverse events. Started Feb 2015; status: completed.
02
Drugs
ATX2417
03
Conditions
asthmaatopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02316912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316912.